Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients.
In a retrospective study of 60 renal-transplant patients immunosuppressed with cyclosporin no specific clinical features differentiated allograft dysfunction responsive to anti-rejection therapy from dysfunction responsive to reduction in cyclosporin dosage. Histologically, allograft dysfunction responsive to anti-rejection therapy was strongly associated with diffuse interstitial infiltration by mononuclear cells, oedema, and haemorrhage, vascular endothelial-cell proliferation, and infiltration of arterial walls by mononuclear cells. Arteriolar medial hypertrophy and hyalinosis were more commonly found in biopsy specimens from allografts with dysfunction responsive to reduction in cyclosporin dose than in those with dysfunction responsive to anti-rejection therapy and those with stable or improving function. Whole-blood cyclosporin concentrations were significantly lower in patients with dysfunction reversed by anti-rejection therapy than in those with dysfunction reversed by reduction in cyclosporin dose or in those with stable function. There was, however, considerable overlap between these groups, so that individual cyclosporin measurements were of little diagnostic value.
Taube
D H
DH
Neild
G H
GH
Williams
D G
DG
Cameron
J S
JS
Hartley
B
B
Ogg
C S
CS
Rudge
C J
CJ
Welsh
K I
KI
D000293:Adolescent; D000328:Adult; D000368:Aged; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012189:Retrospective Studies
D003524:Cyclosporins; D008775:Methylprednisolone